RCS - Ondine Biomedical - NHS Trust up for HSJ Award for Steriwave Use

Ondine BiomedicalAnnouncement

12/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250612:nRSL4865Ma&default-theme=true

RNS Number : 4865M  Ondine Biomedical Inc.  12 June 2025

12th June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

NHS Trust up for HSJ Award for Steriwave Use

 

Mid Yorkshire Teaching NHS Trust Shortlisted for HSJ Patient Safety Award for
Cutting Surgical Infections with Ondine's Steriwave Nasal Photodisinfection

 

 

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that the Mid
Yorkshire Teaching NHS Trust (Mid Yorks) has been shortlisted for the
prestigious HSJ Patient Safety Awards following the successful implementation
of Ondine's Steriwave(®) nasal decolonization technology.

 

Introduced to reduce surgical site infections (SSI) in patients undergoing hip
and knee replacement surgeries, the Steriwave intervention was associated with
a remarkable 71% reduction in SSI over a six-month period, along with
significant cost savings and improved patient outcomes.

 

Carolyn Cross, CEO of Ondine:

"We would like to congratulate Dr Stuart Bond, Consultant Antimicrobial
Pharmacist and Director of Innovation at Mid Yorks, and his team for
pioneering the introduction of Steriwave in the NHS. Their work has clearly
demonstrated the clinical benefits of Steriwave and has sparked interest
across NHS hospitals, particularly as antibiotic resistance continues to
rise."

 

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation
at Mid Yorkshire Teaching NHS Trust:

"Being named a finalist is a testament to the hard work and dedication of our
team. Patient safety is at the heart of everything we do, and we're proud to
be recognized at a national level."

 

The shortlisting follows a rigorous judging process conducted by a panel of
healthcare and patient safety experts.

 

Steriwave is a non-invasive and painless light-activated antimicrobial therapy
that destroys harmful pathogens in the nose-a major source of infection-in
minutes. The treatment involves applying the proprietary Steriwave
photosensitive agent to each nostril followed by illumination with a specific
wavelength of red light. Steriwave is immediately effective against bacteria,
viruses, and fungi and does not contribute to antimicrobial resistance,
offering a powerful tool in the fight against healthcare-associated
infections.

 

Organized by the Health Service Journal (HSJ), the Patient Safety Awards
celebrate the teams and individuals going above and beyond to protect patients
from harm, reduce risks, and embed a culture of safety across the UK
healthcare sector. Winners will be announced at the awards ceremony later this
year.

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUAORRVNUNAUR